Skip to main content
Premium Trial:

Request an Annual Quote

UPDATE: IGC, NCH Awarded Nearly $80M for TCGA Support

This article replaces an earlier version that reported funding solely for IGC.

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The International Genomics Consortium (IGC) in Phoenix, Ariz., and the Research Institute at Nationwide Children's Hospital (NCH) in Columbus, Ohio, have been awarded stimulus grants from the National Institutes of Health totaling nearly $80 million over five years to support the Cancer Genome Atlas Program.

IGC and NCH will manage biospecimens and samples for TCGA, as well as provide support services to the National Cancer Institute for researchers involved in TCGA.

The awards, which are funded in part by the American Recovery and Reinvestment Act, will be spread over five years and will provide IGC up to $37.5 million and NCH up to $41.4 million, if the option to extend is exercised after the base period of 18 months. For the base period, IGC will receive $12.3 million and NCH will receive $11.5 million.

IGC and NCH will provide support services for TCGA by establishing Biospecimen Core Resources (BCRs) for receiving tissue and data from the multiple Tissue Source Site networks. They will provide storage, quality control, processing, and shipping of analytes to genome characterization and sequencing centers for TCGA.

The biospecimen core centers' tasks include being an interface between TCGA and tissue source sites; ensuring and verifying that TCGA subject guidelines and protections have been followed; ensuring that all biospecimens meet standards; collecting clinical information about patients and their cancer samples; extracting and distributing DNA and RNA analytes from tissue samples and sending them to sequencing and characterization centers; and contributing to the leadership of the overall TCGA project.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.